Ignite Creation Date:
2024-05-05 @ 5:15 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00411372
Status:
WITHDRAWN
Last Update Posted:
2015-02-23
First Post:
2006-12-13
Brief Title:
Shortness Of Breath Questionnaire Validation Study
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Randomized Double-blind Parallel-group Study of Fluticasone PropionateSalmeterol Combination FSC 25050mcg Twice Daily and Salmeterol SAL 50mcg Twice Daily to Validate a New Shortness of Breath Questionnaire in Patients With Chronic Obstructive Pulmonary Disease COPD
Status:
WITHDRAWN
Status Verified Date:
2015-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
No subjects enrolled Study was canceled before active
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will last for approximately 8 weeks and will involve 4 visits The study is being carried out to validate a shortness of breath questionnaire
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None